Table 2.
LncRNAs and their roles in ATC
| LncRNA | Tumor suppressor | Oncogene | CSC properties |
|---|---|---|---|
| AK139328 | − | + | N/D |
| BANCR | − | + | + |
| CASC2 | + | − | N/D |
| FOXD2-AS1 | − | + | + |
| GAS5 | + | − | N/D |
| H19 | − | + | N/D |
| HCP5 | − | + | N/D |
| HOTAIR | + | − | + |
| HOTAIRM1 | − | + | N/D |
| KLHL14-AS | + | − | N/D |
| Linc00210 | − | + | N/D |
| LINC00312 | + | − | N/D |
| LOC100507661 | − | + | N/D |
| MALAT1 | − | + | + |
| MANCR | − | + | + |
| MIR22HG | + | − | N/D |
| NEAT1 | − | + | N/D |
| PAR5 | + | − | + |
| PCA3 | − | + | N/D |
| PTCSC3 | + | − | + |
| PVT1 | − | + | + |
| ROR | − | + | + |
| SNHG15 | + | − | N/D |
| SNHG7 | − | + | N/D |
| TNRC6C-AS1 | − | + | N/D |
| TUG1 | − | + | + |
| UCA1 | − | + | N/D |
| XIST | − | + | N/D |
| ZFAS1 | − | + | N/D |
N/D, not detected; BANCR, BRAF-activated non-protein coding RNA; CASC2, cancer susceptibility candidate 2; CSC, cancer stem cell; FOXD2-AS1, FOXD2 adjacent opposite strand RNA 1; GAS5, growth arrest special 5; HCP5, HLA complex P5; HOTAIR, HOX transcript antisense RNA; HOTAIRM1, hox antisense intergenic RNA myeloid 1; Klhl14, kelch like family member 14; Linc00210, long intergenic non-protein coding RNA 210; LINC00312, long intergenic non-protein coding RNA 312; LncRNA, long noncoding RNA, MALAT1: metastasis-associated lung adenocarcinoma transcript 1; MANCR, mitotically associated long non coding RNA; MIR22HG, MIR22 host gene; NEAT1, nuclear paraspeckle assembly transcript 1; PAR5, Prader Wili/Angelman region RNA 5; PCA3, prostate cancer antigen 3; PTCSC3, papillary thyroid carcinoma susceptibility candidate 3; PVT1, plasmacytoma variant translocation 1; ROR, regulator of reprogramming; SNHG15, small nucleolar RNA host gene 15; SNHG7, small nucleolar RNA host gene 7; TNRC6C-AS1, TNRC6C antisense RNA 1; TUG1, taurine up-regulated gene 1;UCA1, urothelial carcinoma-associated 1; XIST, X inactive specific transcript; ZFAS1, ZNFX1 antisense RNA 1